Pluri (NASDAQ:PLUR) Shares Up 2.1% – Still a Buy?

Pluri Inc. (NASDAQ:PLUR)’s stock price shot up 2.1% during mid-day trading on Tuesday . The company traded as high as $3.48 and last traded at $3.4090. 6,687 shares traded hands during trading, a decline of 21% from the average session volume of 8,427 shares. The stock had previously closed at $3.34.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pluri in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Pluri currently has a consensus rating of “Hold” and an average price target of $12.00.

Pluri Stock Performance

The firm has a 50 day simple moving average of $3.44 and a two-hundred day simple moving average of $3.55.

Pluri (NASDAQ:PLUR) last announced its earnings results on Thursday, February 12th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.06). The business had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.64 million.

Institutional Trading of Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC acquired a new position in Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri as of its most recent filing with the SEC. 16.59% of the stock is currently owned by institutional investors.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.